Natco Pharma Ltd. Faces Bearish Momentum Amid Technical Downgrade

Technical Trend Overview

Recent technical assessments reveal that Natco Pharma’s overall trend has deteriorated from mildly bearish to outright bearish. The daily moving averages have turned decisively negative, reinforcing downward momentum. The stock closed at ₹902.40, down from the previous close of ₹952.25, with intraday trading ranging between ₹885.75 and ₹962.25. This decline places the stock closer to its 52-week low of ₹789.30, well below its 52-week high of ₹1,226.10, underscoring the pressure on the share price.

MACD and Momentum Indicators

The Moving Average Convergence Divergence (MACD) indicator presents a mixed picture. On a weekly basis, the MACD remains bearish, signalling sustained selling pressure. However, the monthly MACD is mildly bullish, suggesting some longer-term underlying strength that has yet to translate into price gains. This divergence between weekly and monthly MACD readings indicates that while short-term momentum is weak, there may be a nascent recovery potential if conditions improve.

RSI and Bollinger Bands Analysis

The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, hovering in neutral territory. This lack of directional RSI momentum implies that the stock is neither oversold nor overbought, leaving room for further downside or a potential rebound depending on market catalysts.

Bollinger Bands, however, are firmly bearish on both weekly and monthly timeframes. The stock price is trading near the lower band, indicating increased volatility and a bearish bias. This technical setup often precedes either a continuation of the downtrend or a volatility-driven reversal, but given other bearish signals, the former appears more likely in the near term.

Moving Averages and KST Indicator

Daily moving averages have turned bearish, signalling that short-term price action is under pressure. This is a critical factor for traders who rely on moving average crossovers to time entries and exits. The KST (Know Sure Thing) indicator, which measures momentum across multiple timeframes, is bearish on a weekly basis but mildly bullish monthly. This again highlights the contrast between short-term weakness and potential longer-term stability.

Dow Theory and On-Balance Volume (OBV)

According to Dow Theory, the weekly trend is mildly bearish, while the monthly trend remains mildly bullish. This suggests that while the immediate outlook is cautious, the broader market context may still support a gradual recovery. On-Balance Volume (OBV) shows no clear trend on either weekly or monthly charts, indicating that volume is not confirming price moves decisively. This lack of volume confirmation often signals uncertainty among investors.

Comparative Performance Against Sensex

Natco Pharma’s recent returns have lagged behind the benchmark Sensex index. Over the past week, the stock declined by 1.61% compared to the Sensex’s 0.62% fall. Over one month, the stock dropped 7.15%, while the Sensex gained 1.24%. Year-to-date, Natco Pharma’s return is nearly flat at -0.13%, whereas the Sensex has fallen 8.46%. Over one year, the stock has outperformed the Sensex with a 3.10% gain versus the index’s 3.21% loss. However, over longer horizons such as three and five years, Natco Pharma has underperformed significantly, with a 9.54% gain against Sensex’s 19.28% and a 9.00% loss versus Sensex’s 40.72% gain respectively. Over ten years, the stock’s 42.33% return pales in comparison to the Sensex’s 177.10% surge.

Mojo Score and Grade Downgrade

MarketsMOJO has downgraded Natco Pharma’s Mojo Grade from Hold to Sell as of 4 Aug 2026, reflecting the deteriorating technical and fundamental outlook. The current Mojo Score stands at 33.0, a relatively low rating that signals caution for investors. The company’s small-cap market capitalisation further adds to the risk profile, as smaller companies tend to exhibit higher volatility and lower liquidity.

Investor Implications and Outlook

Investors should approach Natco Pharma with caution given the prevailing bearish technical signals and recent downgrade in its Mojo Grade. The stock’s failure to sustain levels above ₹950 and its proximity to the lower Bollinger Band suggest that downside risks remain elevated in the short term. The absence of strong volume confirmation and neutral RSI readings further complicate the outlook.

However, the mildly bullish monthly MACD and KST indicators hint at a possible stabilisation or recovery over a longer horizon, provided the company can deliver positive fundamental developments or sector tailwinds. The Pharmaceuticals & Biotechnology sector remains competitive and sensitive to regulatory and innovation cycles, which could influence Natco Pharma’s trajectory.

Comparatively, the stock’s underperformance against the Sensex over multiple timeframes highlights the need for investors to consider alternative opportunities within the sector or broader market. The downgrade to a Sell rating by MarketsMOJO reinforces this view, signalling that the risk-reward profile is currently unfavourable.

Summary

Natco Pharma Ltd. is currently navigating a challenging technical landscape marked by bearish momentum across key indicators such as MACD, moving averages, and Bollinger Bands. While some monthly indicators suggest mild bullishness, the overall trend remains negative, reflected in the stock’s recent price decline and downgrade to a Sell rating. Investors should weigh these technical signals alongside sector dynamics and consider peer comparisons before making allocation decisions.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →